Connect with a sales representative
Now Approved for CIDP

In adults with chronic inflammatory demyelinating polyneuropathy

Learn about Hizentra for CIDP

Hizentra Allows Flexible Dosing— Up to Every 2 Weeks

Hizentra is approved for use as often as daily or up to every 2 weeks, enabling you to partner with your patients to design a personalized treatment plan. As their needs change over time, you can adjust dosing frequency and still maintain consistent Ig levels.

Meet Four Patients With Four Different Infusion Schedules...

Every 2 Weeks

Will is a college student who chooses to infuse every 2 weeks due to privacy concerns

Weekly

Sarah is a busy mother who prefers a convenient weekly infusion schedule

Every 10 Days

Rose enjoys traveling and likes to infuse on the 5th, 15th, and 25th of each month for convenience

2x per Week

Kevin is an active second-grader with low body mass on a frequent infusion schedule

Hizentra Is Designed to Deliver Steady-state IgG Levels Whether Given Daily or Up to Every 2 Weeks

Hizentra maintains consistent IgG levels vs IVIg4†

Chart plotting Hizentra steady-state Ig levels vs IVIg every 4 weeks
 Reproduced from Wasserman RL, Melamed I, Nelson RP Jr, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011;50(6):405-414. With permission of Springer.
 The weekly dose of Hizentra was 153% of the previous weekly equivalent dose of IVIg.
*Comparison of mean (±SE) serum IgG concentrations with intravenous IgPro10 and subcutaneous IgPro20. Mean serum IgG concentrations measured at weeks 8–16 in the IgPro20 study are compared with mean serum IgG concentrations measured before and after infusion 7 for patients with a 4-week schedule in the IgPro10 study (data from 24 or 25 patients were available for all data points except day 28, when n=21). Mean IgPro20 dose was 202.3 mg/kg body weight; mean IgPro10 dose was 156.1 mg/kg body weight. SE=standard error.
No difference in the clinical benefit of SCIg and IVIg serum profiles has been demonstrated by substantial clinical evidence or experience.

Clinical Perspectives:
Discussion of IVIg & SCIg

Carla Duff, ARNP, discusses the differences between each route of administration and how these differences are integral in customizing therapy for each patient's needs.

You are now leaving the current website.

Do you want to continue?

No Yes